<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256282</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 02-23</org_study_id>
    <secondary_id>2002-2763</secondary_id>
    <secondary_id>NCI-2010-00217</secondary_id>
    <nct_id>NCT00256282</nct_id>
  </id_info>
  <brief_title>Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma</brief_title>
  <official_title>A Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John P. Fruehauf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who
      have metastatic melanoma which has advanced beyond the point at which local therapies such as
      surgery or radiation therapy would be helpful. Without effective treatment, metastatic
      melanoma is usually a severe and fatal disease. Chemotherapy agents or combinations of
      chemotherapy agents have produced tumor shrinkage in some patients, which has occasionally
      persisted. This research involves treatment with a combination of chemotherapy drugs known to
      be active against melanoma alone. The investigational purpose of this study is to determine
      if the combination of docetaxel, vinorelbine and sargramostim will produce a response
      (complete or partial) in metastasis melanoma. The researchers also wants to find out what
      side effects are associated with this combination of drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Annually in the U.S. there is an estimated 40,000 new cases of malignant melanoma and 7000
      deaths. This disease is becoming more common with its incidence increasing at a more rapid
      rate in the past decade than that of any other cancer except lung cancer in women. Metastatic
      disease responds poorly to the usual treatments with only 2 out of 30 drugs tested, DTIC and
      nitrosoureas, showing response rates greater than 10%. Complete responses are rare.

      Metastatic melanoma is a disease with few therapeutic options. Multi-agent chemotherapy with
      cisplatin (CDDP), Dacarbazine (DTIC), Carmustine (BCNU), with or without Tamoxifen, offers a
      20% response rate but has failed to consistently demonstrate a significant improvement in
      overall survival (OS) or disease-free survival (DFS) when compared to a single agent DTIC.

      Recently, investigators, in an effort to combine the activity of biologic response modifiers
      with chemotherapy, have developed combination biochemotherapy for metastatic melanoma. Legha
      et al reported an overall objective response rate of 64% with a 5-day biochemotherapy
      regimen. O'Day et al reported similar results (overall response rate of 57%) using a modified
      5-day biochemotherapy regimen.

      The above regimens all have significant toxicities and modest response rates. Clearly, more
      effective less toxic regimens are needed.

      Vinorelbine tartrate (Navelbine) and Docetaxel (Taxotere) have both shown activity against
      melanoma. Additionally, the combination of both drugs has shown enhanced activity against
      melanoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage) Systemic Therapy</measure>
    <time_frame>Six months from initial treatment</time_frame>
    <description>The primary endpoint is to evaluate the six-month progression-free survival (PFS) in patients with AJCC stage IV metastatic melanoma treated with docetaxel and vinorelbine as first-line or post-first line (salvage) systemic therapy. Progressive disease is defined as any new lesion or a greater than or equal to 20% increase in the largest perpendicular diameter of the sum of the T-lesions identified on contrast enhanced CT or MRI scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Alive at One Year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel &amp; Vinorelbine + Sargramostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, Vinorelbine, and Sargramostim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>30 mg/m2 IV over 6-10 min every 14 days</description>
    <arm_group_label>Docetaxel &amp; Vinorelbine + Sargramostim</arm_group_label>
    <other_name>Navelbine</other_name>
    <other_name>NSC-608210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>40mg/m2 IV over 1 hour every 14 days</description>
    <arm_group_label>Docetaxel &amp; Vinorelbine + Sargramostim</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>RP56976</other_name>
    <other_name>NSC-628503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days</description>
    <arm_group_label>Docetaxel &amp; Vinorelbine + Sargramostim</arm_group_label>
    <other_name>Recombinant GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Immunex</other_name>
    <other_name>NSC-613795</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18

          -  Karnofsky Performance Status (KFS) of greater than or equal to 70

          -  Laboratory values (performed in 14 days, inclusive prior to study drug
             administration):

               -  Absolute neutrophil count (ANC) &gt;1500/mm3

               -  Platelet count &gt;100,000/mm3

               -  Hemoglobin &gt; 10 g/dl

               -  Blood urea nitrogen (BUN) and serum creatinine &lt; 0.5 times the upper limit of
                  laboratory normal

               -  Total and direct bilirubin &lt; 1.5 times the upper limit of laboratory normal

               -  Serum glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic
                  transaminase(SGPT) &lt; 3 times the upper limit of laboratory normal

               -  Alkaline phosphatase &lt; 3 times upper limit of laboratory normal

          -  Life expectancy of greater than 12 weeks

          -  Written informed consent

        Exclusion Criteria:

          -  No recovery from all active toxicities of prior therapies

          -  Surgery within 1 week prior to study drug administration, providing acute surgical
             toxicity is resolved

          -  Subjects within acute infection treated with intravenous antibiotics

          -  Frequent vomiting or medical condition that could interfere with oral medication
             intake (e.g., partial bowel obstruction)

          -  Concurrent malignancies at other sites with the exception of surgically cured
             carcinoma in situ (CIS ) of the cervix, basal or squamous cell carcinoma of the skin,
             and prior malignancies which have not required anit-tumor treatment within the
             preceding 24 months

          -  Known HIV-positivity or AIDS-related illness

          -  Women of childbearing potential who are not using an effective method of contraception
             (eligible patients must have a negative urine pregnancy test 24 hours prior to
             administration of study drug and be practicing medically approved contraceptive
             precautions)

          -  Men who do not use an effective method of contraception.

          -  Chemotherapy within four weeks prior to study drug administration or biologic
             therapy/immunotherapy within two weeks prior to study drug administration

          -  Completion of radiation therapy, interstitial brachytherapy, or radiosurgery within 4
             weeks prior to study drug administration (patients with brain metastases from melanoma
             must have completed radiotherapy to the brain at least 3 weeks before study commences)

          -  Bone metastases as sole reason for Stage IV disease

          -  Karnofsky Performance Status of less than or equal to 60
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Fruehauf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol. 2011 Oct;68(4):1081-7. doi: 10.1007/s00280-011-1703-z. Epub 2011 Jul 19.</citation>
    <PMID>21769667</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>December 31, 2016</results_first_submitted>
  <results_first_submitted_qc>May 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2018</results_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>John P. Fruehauf</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Metastatic Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel and Vinorelbine Plus Sargramostim</title>
          <description>Docetaxel (40 mg.m2 IV), Vinorelbine (30 mg/m2 IV), and Sargramostim 250 mcg/m2 subcutaneous (SQ)
Vinorelbine: 30 mg/m2 IV over 6-10 min every 14 days
Docetaxel: 40mg/m2 IV over 1 hour every 14 days
Sargramostim: 250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression, relapse during acti</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel and Vinorelbine Plus Sargramostim</title>
          <description>The DVS regimen consisted of docetaxel 40 mg/m2 IV over 1 hour, vinorelbine 30 mg/m2 IV over 6 to 10 minutes on day 1, every 14 days, and GM-CSF, 250 mg/m2 SC on days 2 to 12. Patients received a cycle of this regimen every two weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" lower_limit="24" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage) Systemic Therapy</title>
        <description>The primary endpoint is to evaluate the six-month progression-free survival (PFS) in patients with AJCC stage IV metastatic melanoma treated with docetaxel and vinorelbine as first-line or post-first line (salvage) systemic therapy. Progressive disease is defined as any new lesion or a greater than or equal to 20% increase in the largest perpendicular diameter of the sum of the T-lesions identified on contrast enhanced CT or MRI scan.</description>
        <time_frame>Six months from initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Vinorelbine Plus Sargramostim</title>
            <description>Docetaxel (40 mg.m2 IV), Vinorelbine (30 mg/m2 IV), and Sargramostim 250 mcg/m2 subcutaneous (SQ)
Vinorelbine: 30 mg/m2 IV over 6-10 min every 14 days
Docetaxel: 40mg/m2 IV over 1 hour every 14 days
Sargramostim: 250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage) Systemic Therapy</title>
          <description>The primary endpoint is to evaluate the six-month progression-free survival (PFS) in patients with AJCC stage IV metastatic melanoma treated with docetaxel and vinorelbine as first-line or post-first line (salvage) systemic therapy. Progressive disease is defined as any new lesion or a greater than or equal to 20% increase in the largest perpendicular diameter of the sum of the T-lesions identified on contrast enhanced CT or MRI scan.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" lower_limit="91" upper_limit="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Alive at One Year</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Vinorelbine Plus Sargramostim</title>
            <description>Docetaxel (40 mg.m2 IV), Vinorelbine (30 mg/m2 IV), and Sargramostim 250 mcg/m2 subcutaneous (SQ)
Vinorelbine: 30 mg/m2 IV over 6-10 min every 14 days
Docetaxel: 40mg/m2 IV over 1 hour every 14 days
Sargramostim: 250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Alive at One Year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years, 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel and Vinorelbine Plus Sargramostim</title>
          <description>Docetaxel (40 mg.m2 IV), Vinorelbine (30 mg/m2 IV), and Sargramostim 250 mcg/m2 subcutaneous (SQ)
Vinorelbine: 30 mg/m2 IV over 6-10 min every 14 days
Docetaxel: 40mg/m2 IV over 1 hour every 14 days
Sargramostim: 250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="40" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropathy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John P. Fruehauf</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>714-456-5153</phone>
      <email>jfruehau@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

